{{Rsnum
|rsid=6493497
|Gene=CYP19A1
|Chromosome=15
|position=51338638
|Orientation=plus
|GMAF=0.1947
|Gene_s=C14orf176
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 1.8 | 25.9 | 72.3
| HCB | 5.1 | 37.2 | 57.7
| JPT | 4.5 | 30.4 | 65.2
| YRI | 9.5 | 39.5 | 51.0
| ASW | 7.0 | 36.8 | 56.1
| CHB | 5.1 | 37.2 | 57.7
| CHD | 2.8 | 32.1 | 65.1
| GIH | 7.9 | 24.8 | 67.3
| LWK | 9.1 | 46.4 | 44.5
| MEX | 0.0 | 24.1 | 75.9
| MKK | 8.3 | 50.0 | 41.7
| TSI | 3.9 | 25.5 | 70.6
| HapMapRevision=28
}}{{PMID Auto
|PMID=20048079
|Title=Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors
|OA=1
}}

{{PharmGKB
|RSID=rs6493497
|Name_s=
|Gene_s=CYP19A1
|Feature=NA
|Evidence=PubMed ID:20048079
|Annotation=Phenotype: This SNP, along with a second one in tight LD (rs71760050) was significantly associated, in a cohort of estrogen-receptor-positive patients with primary breast cancer larger than 3 cm, with change in aromatase activity before and after aromatase inhibitor neoadjuvant treatment . It was also associated, but not significantly so after adjustment for multiple testing, with change in estrone level and with pretreatment aromatase level. Study size: 45. Study population/ethnicity: Edinburgh female ER-positive patients, primary breast cancer larger than 3 cm. Significance metric(s): nominal p = 0.0063, p = 0.039 after adjustment for multiple testing. Type of association: PD; GN;FA. Second Phenotype: In a group of 200 women with early-stage breast cancer, who were treated with 1 mg/day adjuvant anastrozole, this SNP was significantly associated with pre-drug and post-drug estradiol plasma concentrations after adjusting for plasma anastrozole concentrations. Study size: 200. Study population: women with early-stage breast cancer (Mayo Clinic-M.D. Anderson pharmacogenomic study participants) . Significance metric(s):pre-drug p = 0.028; post-drug p = 0.0002. Type of association: PD; GN;FA
|Drugs=anastrozole; exemestane; letrozole
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165260357
}}

{{PMID Auto
|PMID=21939764
|Title=Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6493497
|overall_frequency_n=31
|overall_frequency_d=128
|overall_frequency=0.242188
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=25
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23408108
|Title=Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}